In what could be seen as a coup, ventricular assist device maker Thoratec (Pleasanton, California) reported last month that the FDA granted it a virtually condition-free approval of its investigational device exemption (IDE) for the company to begin a Phase II pivotal clinical trial for its next generation HeartMate II LVAS (Left Ventricular Assist System).